

Contents

<i>Contributor contact details</i>	xv
<i>Introduction</i>	xxi
A. ATALA, Wake Forest Institute for Regenerative Medicine, USA	
Part I Basic principles of stem cells	1
1 Basic principles for stem cell culture	3
J. DAVIS, University of Hertfordshire, UK	
1.1 Introduction	3
1.2 Understanding and standardization of <i>in vitro</i> culture systems	4
1.3 Quality assurance	12
1.4 Documentation	17
1.5 Safety	18
1.6 Legal, ethical and regulatory compliance	22
1.7 Education and training	22
1.8 Conclusion	24
1.9 Acknowledgement	24
1.10 References	24
2 Basic principles of human embryonic stem cells	29
D. ILIC, D. STEVENSON, H. PATEL and P. BRAUDE, King's College London School of Medicine, UK	
2.1 Introduction: biological properties of human embryonic stem cells (hESC)	29
2.2 Historical overview	32
2.3 Human embryonic stem cells (hESC) in therapy – current status and strategies for the future	35

viii	Contents	
2.4	Human embryonic stem cells (hESC) in drug discovery – current status and strategies for the future	37
2.5	Specific mutation-carrying (SMC) human embryonic stem cells (hESC)	39
2.6	Human embryonic stem cells (hESC) utilization, the next step	42
2.7	Conclusion	43
2.8	References and further reading	43
2.9	Internet references	47
3	Basic principles in generating induced pluripotent stem cells K. SIDHU, University of New South Wales, Australia	49
3.1	Introduction	49
3.2	Evolution of reprogramming and the birth of induced pluripotency	50
3.3	Current methods for induced reprogramming	52
3.4	Conclusions and future prospects	58
3.5	References	59
4	Basic principles of amniotic fluid and placenta stem cells A. ATALA, Wake Forest Institute for Regenerative Medicine, USA	64
4.1	Introduction	64
4.2	Amniotic fluid and placenta in developmental biology	65
4.3	Isolation and characterization of progenitor cells	66
4.4	Differentiation of amniotic fluid- and placenta-derived progenitor cells	67
4.5	<i>In vivo</i> behavior of amniotic fluid stem cells	71
4.6	Amniotic fluid and placenta for cell therapy	72
4.7	Conclusion	72
4.8	Acknowledgment	73
4.9	References	73
5	Basic principles of cord blood stem cells P. HOLLANDS, University of Westminster, UK	77
5.1	Introduction: history of cord blood stem cell technology	77
5.2	Cord blood collection, processing and storage	78
5.3	Public and private cord blood banking	80
5.4	Cord blood haemopoietic stem cell transplantation	82

5.5	Cord blood mesenchymal stem cells	84
5.6	Current research and future developments	85
5.7	Cord blood transfusion	88
5.8	Conclusion	89
5.9	References	89
6	Basic principles of multipotent stem cells A. KUMAR and C. VERFAILLIE, Katholieke Universiteit Leuven, Belgium	100
6.1	Introduction	100
6.2	Hematopoietic stem cells (HSC)	101
6.3	Mesenchymal stem cells (MSC)	101
6.4	Adult stem cells with broader potential	103
6.5	<i>In vitro</i> and <i>in vivo</i> differentiation potential of multipotent adult progenitor cells (MAPC)	107
6.6	Immunomodulatory properties of multipotent adult progenitor cells (MAPC)	109
6.7	Conclusion	110
6.8	References	110
Part II	Enabling cell therapy	119
7	Intellectual property claims to stem cell technologies: research, clinical testing and product sales A. M. HAMMERSLA and M. L. ROHRBAUGH, National Institutes of Health, USA	121
7.1	Introduction	121
7.2	International overview of patent laws and stem cell policies	123
7.3	Introduction to the international stem cell patent landscape	135
7.4	Human embryonic stem cell patents	138
7.5	Advances in induced pluripotent stem cell patents (iPS cells)	139
7.6	Models for access to, and management of, stem cell patents	141
7.7	Conclusion	143

x	Contents	
7.8	Acknowledgments	144
7.9	References	144
8	Regulatory considerations of stem and progenitor cell-based products: US Food and Drug Administration	147
	D. W. FINK, S. R. BAUER, P. AU, C. C. HAUDENSCHILD, M. H. LEE and B. K. MCCRIGHT, Center for Biologics Evaluation and Research, US-FDA, USA	
8.1	Introduction	147
8.2	Preparing the cellular component: chemistry, manufacturing and control considerations	148
8.3	Preclinical testing: pharmacology/toxicology considerations	154
8.4	Clinical trial considerations	158
8.5	Combination products: considerations when combining stem/progenitor cells with other components	161
8.6	Conclusion and future regulatory tools development	164
8.7	Acknowledgments	166
8.8	References	166
9	Cell therapy commercialisation	169
	D. BRINDLEY and C. MASON, University College London, UK	
9.1	Introduction: cells as therapies	169
9.2	The field to date	176
9.3	Commercialisation	184
9.4	Manufacturing	196
9.5	Future trends	199
9.6	Conclusion	200
9.7	Acknowledgements	201
9.8	Sources of further information	201
9.9	References	202
10	Stem cell tourism	206
	A. ZARZECZNY, University of Regina, Canada and C. RACHUL and T. CAULFIELD, University of Alberta, Canada	
10.1	Introduction	206
10.2	Scope of the phenomenon	209
10.3	Problems relating to stem cell tourism	214
10.4	Responses	221

10.5	Conclusion	226
10.6	Acknowledgments	227
10.7	References	227
Part III Tissue-specific progenitor cells		235
11	Adipose tissue-derived stem cell biology and therapy R. MADONNA and R. DE CATERINA, 'G. d'Annunzio' University, Italy	237
11.1	Introduction	237
11.2	Characterization of adipose tissue-derived stromal cells	245
11.3	Advantages of adipose tissue-derived stem cells over other cell sources	250
11.4	Adipose tissue-derived stromal cells for cardiovascular repair: a joint clinical and experimental approach	251
11.5	Conclusion: perspectives and open questions	257
11.6	Acknowledgements	258
11.7	References	258
12	Umbilical cord blood (UCB) progenitor and stem cell biology and therapy M. SHAHADUZZAMAN and A. E. WILLING, University of South Florida, USA	263
12.1	Introduction	263
12.2	Biological characterization of umbilical cord blood (UCB) stem/progenitor cells	264
12.3	Therapeutic potential of umbilical cord blood (UCB) stem/progenitor cells for tissue repair or regeneration	270
12.4	Conclusion and future perspectives	275
12.5	References	275
13	Auditory progenitor stem cell biology and therapy L. ABBAS and M. N. RIVOLTA, University of Sheffield, UK	282
13.1	Introduction	282
13.2	Sources of auditory progenitors	283
13.3	Transdifferentiation or developmental progression?	287
13.4	Which is the best cell type and stage for transplantation?	294
13.5	Future trends	299
13.6	References	300

14	Olfactory mucosa: neural stem and progenitor cells for nervous system repair and cell models of brain disease	309
	A. MACKAY-SIM, Griffith University, Australia	
14.1	Introduction	309
14.2	Olfactory mucosa as source of tissue-resident stem cells	309
14.3	Cells with clinical application	315
14.4	Preclinical and clinical studies	317
14.5	Olfactory stem cell models of human disease	319
14.6	Conclusion	323
14.7	Acknowledgements	324
14.8	References	324
15	Oral cavity progenitor and stem cell biology and therapy	331
	W. ZHANG and P. C. YELICK, Tufts University, USA	
15.1	Introduction	331
15.2	Embryonic development of teeth and supporting tissues	332
15.3	Tooth bud-derived stem cell types and differentiation potential	333
15.4	Stem cells present in postnatal teeth	335
15.5	Unsolved problems in the use of dental stem cells	339
15.6	Conclusion	340
15.7	References	341
16	Bone marrow mesenchymal progenitor and stem cell biology and therapy	345
	T. LEE, University at Buffalo, USA	
16.1	Introduction	345
16.2	Mesenchymal stem cell (MSC) biology	346
16.3	Mesenchymal stem cell (MSC) therapy	359
16.4	Conclusion	368
16.5	References	369
17	Progenitor and stem cell therapies for cartilage repair	391
	S. SAHA, J. KIRKHAM, D. J. WOOD and X. B. YANG, University of Leeds, UK	
17.1	Introduction	391
17.2	Cell-based therapies for cartilage repair	393
17.3	Tissue engineering strategies for cartilage repair	405

17.4	Hurdles for cartilage tissue regeneration	406
17.5	Conclusion and future trends	407
17.6	Acknowledgement	408
17.7	References	408
18	Cardiac stem and progenitor cell biology and therapy	418
	D. NURZYNSKA, C. CASTALDO, S. MONTAGNANI and F. DI MEGLIO, University of Naples 'Federico II', Italy	
18.1	Introduction: current concept of cardiac tissue homeostasis	418
18.2	From none to plenty: cardiac stem/progenitor cell populations within adult myocardium	420
18.3	Origin of cardiac stem cells in the adult human heart	423
18.4	Cardiac stem cell niche	426
18.5	Regeneration boosting	427
18.6	Conclusions	434
18.7	References	434
19	Renal progenitor and stem cell biology and therapy	443
	L. M. YAMALEYEVA, S.-H. MIRMALEK-SANI, A. ATALA and J. J. YOO, Wake Forest University Health Sciences, USA	
19.1	Introduction	443
19.2	Endogenous renal progenitor cells and regeneration	445
19.3	Summary and conclusions	455
19.4	References	456
20	Lung progenitor and stem cell biology and therapy	463
	I. P. NEURINGER, Massachusetts General Hospital, USA	
20.1	Introduction: definitions of a diverse population	463
20.2	Lung development and stem cell zones	464
20.3	Resident lung stem cells and their niches	465
20.4	Circulating bone marrow-derived stem cells which home to the lung	475
20.5	Techniques for identification of lung stem cells	477
20.6	Disorders of lung stem cells and clinical applications in lung diseases	478
20.7	Induced pluripotent stem cells (iPSCs)	487
20.8	Conclusion: future directions for lung stem cells through bioengineered lung tissue	488
20.9	Acknowledgments	490
20.10	References	490

21	Genitourinary progenitor and stem cell biology and therapy	501
	A. ATALA, Wake Forest Institute for Regenerative Medicine, USA	
21.1	Introduction	501
21.2	The basics of tissue engineering	502
21.3	Cells for use in urological tissue engineering	502
21.4	Biomaterials for urological tissue engineering	507
21.5	Tissue engineering of specific urologic structures	508
21.6	Conclusion	518
21.7	Acknowledgments	518
21.8	References	518
	Index	526